TCGA-B6-A0WS-01A-11R-A115-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 99
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.530
- INTERFERON_GAMMA_RESPONSE+0.490
- ALLOGRAFT_REJECTION+0.460
- APICAL_SURFACE+0.420
- IL6_JAK_STAT3_SIGNALING+0.350
- TGF_BETA_SIGNALING+0.350
- ESTROGEN_RESPONSE_EARLY+0.330
- HEDGEHOG_SIGNALING+0.330
- IL2_STAT5_SIGNALING+0.320
- APOPTOSIS+0.310
Top 10 suppressed
- MYC_TARGETS_V2-0.280
- E2F_TARGETS-0.240
- MYC_TARGETS_V1-0.240
- PANCREAS_BETA_CELLS-0.210
- OXIDATIVE_PHOSPHORYLATION-0.200
- SPERMATOGENESIS-0.160
- G2M_CHECKPOINT-0.130
- KRAS_SIGNALING_DN-0.110
- MTORC1_SIGNALING-0.100
- FATTY_ACID_METABOLISM-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-F7-8489-01A-31R-2403-07 | — | — | 0.885 |
| 2 | BS_9DFBHHB5 | low-grade glioma | — | 0.879 |
| 3 | TCGA-CR-7395-01A-11R-2016-07 | — | — | 0.860 |
| 4 | TCGA-EW-A1PE-01A-11R-A144-07 | — | B | 0.859 |
| 5 | 653522fe-3289-4e1f-9373-c81f923893a3 | — | — | 0.858 |
| 6 | TCGA-50-5941-01A-11R-1755-07 | — | cohortA1 | 0.858 |
| 7 | R223 | — | — | 0.854 |
| 8 | MDT-AP-2029 | Med | Medulloblastoma | 0.847 |
| 9 | BS_014EVM2D | low-grade glioma | — | 0.846 |
| 10 | TCGA-BA-5556-01A-01R-1514-07 | — | — | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.420 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.330 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |